Table 5 Annual direct medical costs attributable to T2D according to main resource categories among study participants in Bahrain
From: Type 2 diabetes and healthcare resource utilisation in the Kingdom of Bahrain
| Â | For each patient | Total population | For each patient | Total population |
|---|---|---|---|---|
BHD (95% CI) | USD (95% CI) | Million BHD (95% CI) | Million USD (95% CI) | |
Admissions | 690 (485–895) | 1831 (1287–2374) | 62.2 (43.7–80.6) | 165.0 (116.0–214.0) |
Procedures | 173 (122–225) | 460 (323–598) | 15.6 (11.0–20.3) | 41.5 (29.1–53.9) |
Outpatient visits | 101 (94–108) | 269 (250–288) | 9.1 (8.5–9.8) | 24.2 (22.5–26.0) |
Laboratory tests | 82 (75–89) | 218 (200–235) | 7.4 (6.8–8.0) | 19.6 (18.0–21.2) |
Oral antidiabetic medicine | 49 (46–51) | 130 (122–137) | 4.4 (4.2–4.6) | 11.7 (11.0–12.3) |
Insulin and other injectables | 42 (34–51) | 113 (91–134) | 3.8 (3.1–4.6) | 10.2 (8.2–12.1) |
Other oral medicine | 21 (10–24) | 57 (49–65) | 1.9 (1.7–2.2) | 5.1 (4.4–5.8) |
Self-monitoring | 2 (945–1379) | 6 (4–9) | 0.2 (0.13–0.3) | 0.56 (0.34–0.78) |
Total costsa | 1162 (945–1379) | 3084 (2507–3659) | 104.7 (85.1–124.2) | 277.8 (225.9–329.7) |